Mallinckrodt PLC (MNK) Given Average Recommendation of “Hold” by Brokerages
Mallinckrodt PLC (NYSE:MNK) has received a consensus recommendation of “Hold” from the twenty-two ratings firms that are covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have given a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $39.52.
Several equities analysts have recently weighed in on the company. Barclays downgraded Mallinckrodt from an “equal weight” rating to an “underweight” rating and cut their target price for the company from $23.00 to $20.00 in a research report on Friday, February 2nd. ValuEngine downgraded Mallinckrodt from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Zacks Investment Research raised Mallinckrodt from a “strong sell” rating to a “hold” rating in a research report on Tuesday, January 9th. Mizuho reaffirmed a “neutral” rating and issued a $21.00 price objective (down previously from $22.00) on shares of Mallinckrodt in a research report on Tuesday, January 9th. Finally, Cantor Fitzgerald set a $42.00 price objective on Mallinckrodt and gave the company a “buy” rating in a research report on Monday, January 8th.
In other Mallinckrodt news, Director Dr Kneeland Youngblood acquired 4,560 shares of the business’s stock in a transaction on Tuesday, November 28th. The shares were bought at an average price of $21.94 per share, with a total value of $100,046.40. Following the transaction, the director now directly owns 19,789 shares of the company’s stock, valued at approximately $434,170.66. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.53% of the company’s stock.
Mallinckrodt (NYSE:MNK) opened at $15.96 on Wednesday. The firm has a market capitalization of $1,567.58, a P/E ratio of 2.23, a PEG ratio of 0.31 and a beta of 1.04. The company has a current ratio of 1.38, a quick ratio of 1.05 and a debt-to-equity ratio of 1.08. Mallinckrodt has a 12-month low of $15.27 and a 12-month high of $55.32.
Mallinckrodt Company Profile
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.